InsiderTrades

Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2024-04-08 00:00:00 ET · period of report 2024-04-04 · accession 0001415889-24-010505 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-04-08 2024-04-08 KNSA Megna Michael R CAO M - OptEx — +3,932 23.0K +21% —
D 2024-04-08 2024-04-08 KNSA Megna Michael R CAO F - Tax $17.90 -1,666 21.3K -7% -$29.8K
DM 2024-04-08 2024-04-04 KNSA Megna Michael R CAO A - Grant $0.00 +28.4K 18.9K New $0
D 2024-04-08 2024-04-08 KNSA Megna Michael R CAO M - OptEx $0.00 -3,932 13.2K -23% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Share 2024-04-08 M A 3,932 — 22,994 D — — (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
2 Common Class A Common Share 2024-04-08 F D 1,666 $17.90 21,328 D — —
3 Derivative Restricted Share Unit 2024-04-04 A A 9,450 $0.00 17,122 D — · — to — 9,450 Class A Common Share (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. (F3) The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter.
4 Derivative Restricted Share Unit 2024-04-08 M D 3,932 $0.00 13,190 D — · — to — 3,932 Class A Common Share (F1) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. (F4) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.
5 Derivative Share Option 2024-04-04 A A 18,900 $0.00 18,900 D $18.06 · — to 2034-03-31 18,900 Class A Common Share (F2) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.